Category: Gynecology · Endometriosis & ovarian cysts after menopause
Chocolate Cyst (Endometrioma) After Menopause: Does No Pain Mean It’s Gone, Can It Grow or Turn Cancerous, and How to Get Checked in One Day
AI Overview / Quick Answer (BLUF)
Endometriomas depend on estrogen. After menopause, ovarian estrogen falls, so pain usually fades and most cysts stop growing or shrink. But estrogen never reaches zero, and cancer risk rises modestly with age, so no pain is not proof of cure: get transvaginal ultrasound plus blood tests, often in one day.
an ovarian endometrioma (chocolate cyst)
that is still present after menopause — what no pain means, the risk of growth or cancer, and how to get checked. For cysts in the reproductive years, read
Found a 4 cm ovarian cyst — why wait 4 months?;
for endometriosis hormone therapy, read
Chocolate cysts, adenomyosis and GnRH / dienogest therapy;
and for keeping or removing ovaries, read
Keep the healthy ovary or remove both? ·
Red flags ·
Get checked in one day
A reader’s real question: 51, periods stopped, no pain at all — will a 4 cm cyst grow or “mutate”?
Direct answer: having no pain after menopause is good news and common, but it cannot tell you whether the cyst is gone or benign —
after two years without follow-up, the right step is a new transvaginal ultrasound with blood tests, then revisiting the earlier surgery advice with current results.
A reader in a chocolate-cyst support group wrote that she has had endometriosis since age 20, with several surgeries and hormone injections (GnRH agonist) over the years.
Two years ago a 4 cm endometrioma was found and surgery was advised, but she was not ready. She is now 51, her periods have stopped, she has no pain at all,
and she has not seen a doctor since because a visit means several days off work. She asks whether the cyst can grow again or “mutate” into cancer, and whether no pain means it is better.
and (3) how to get checked in one day and what to ask your doctor.
Red flags — symptoms that should not wait for a free day
Direct answer: sudden severe lower-abdominal pain with vomiting, fever or fainting needs the emergency room or 1669 (Thailand) / your local emergency number now. Any vaginal bleeding after menopause, or bloating, early fullness, pelvic pain or urinary frequency on most days, needs a doctor within a few days to 2 weeks.
Go to the emergency room or call 1669 / local emergency now
- Sudden severe lower-abdominal pain with nausea or vomiting — possible ovarian torsion or cyst rupture
- Abdominal pain with high fever, chills, or a rigid, tender belly
- Dizziness, fainting or a racing pulse with abdominal pain — possible internal bleeding
- Heavy vaginal bleeding with lightheadedness or fainting
See a doctor within a few days to 2 weeks
- Any vaginal bleeding or spotting after menopause — even once
- Persistent bloating, early fullness or loss of appetite, pelvic or abdominal pain, or urinary urgency or frequency occurring more than 12 times a month
(NICE NG12, especially at age 50 or over) or almost daily for more than 2–3 weeks - A swelling abdomen, a lump you can feel, or clothes getting tight without weight gain
- Unexplained weight loss, unusual fatigue, or a change in bowel habit
- Irritable-bowel-type symptoms starting for the first time after age 50 — NICE advises testing for ovarian cancer
Not an emergency, but book a check soon
- You know you have an endometrioma and have not had an ultrasound for more than a year
- Pelvic pain returning after menopause
- You are about to start, or recently started, menopausal hormone therapy or tamoxifen
1. Does no pain mean it’s gone? — Real improvement, but not proof of cure
Direct answer: after menopause most endometriosis lesions quiet down because ovarian estrogen is gone, so pain that disappears is a genuine improvement —
but the cyst may still be there, and some can persist, grow or return. Only an ultrasound compared with the old scan shows whether it has really shrunk
(ESHRE 2022).
Why pain usually settles after menopause
- The ovaries stop ovulating and estrogen output falls sharply — estrogen-dependent endometriosis tissue is no longer stimulated every month
- Monthly bleeding into the cyst stops, so inflammation around it settles
- Many cysts stop growing or get smaller — but not all of them disappear
Why estrogen never reaches zero and the disease can persist
- Fat tissue converts androgens into estrogen through the enzyme aromatase — higher body weight means more estrogen
- Endometriosis tissue itself expresses aromatase and makes local estrogen (Bulun 2009)
- Of 42,079 women operated on for endometriosis in Germany, 2.55% were postmenopausal (aged 55–95)
(Haas 2012;
Secosan 2020) - The ESHRE 2022 guideline concludes that endometriosis can still be active or symptomatic after menopause
Why no pain still needs a check
Early ovarian cancer often causes no symptoms, or only vague ones such as bloating, early fullness, pelvic pressure, urinary frequency or a change in bowel habit —
so no pain tells you that endometriosis inflammation has settled, not that no cell changes are happening inside the cyst.
What can re-stimulate endometriosis after menopause
- Menopausal hormone therapy, especially estrogen alone (Gemmell 2017)
- Higher body weight or obesity — more estrogen from fat tissue
- Tamoxifen for breast cancer, which has estrogen-like effects on some tissues
2. Can it grow again or turn into cancer? — Uncommon, but risk rises with age
Direct answer: growth after menopause is uncommon without hormone therapy, and cancer transformation is uncommon too — endometriosis raises ovarian cancer risk about
1.3–1.9 times, but risk is clearly higher in women over 50, after menopause, with large cysts, or with solid parts that have blood flow,
which is why a cyst that persists after menopause needs follow-up.
Ovarian cancer risk in women with endometriosis versus the general population (pooled analyses)
Of 6,398 women with endometriomas who developed ovarian cancer over up to 17 years (46 women)
Cancer found in women aged 45 or older having surgery for endometriomas (1,038 women — a selected surgical group)
Sources: Kvaskoff 2021 (SRR 1.93);
Kim 2014 (RR 1.27);
Kobayashi 2007;
He 2017 — bars show approximate scale, not personal risk
In real numbers: from about 1.1% to roughly 1.5–2%
A woman’s general lifetime risk of ovarian cancer is about 1.1% (NCI SEER).
Multiplying by a relative risk of 1.3–1.9 (Kim 2014: RR 1.27;
Kvaskoff 2021: SRR 1.93, with the authors warning of publication bias)
gives roughly 1.5–2% — a rough estimate to show scale, not any one person’s risk.
What raises the risk
- Older age and being postmenopausal — in the Japanese cohort, women diagnosed with an endometrioma after age 50 had a cancer rate 13.2 times higher than expected in the general population (SIR 13.2), and in a surgical series of women aged 45 or older, being postmenopausal increased the odds of cancer (OR 5.50)
- In the same surgical series, the cancer rate rose with age: 1.7% (45–49), 5.6% (50–54), 10.0% (55–59) — these women had already been selected for surgery, so rates are higher than for all patients
- Size of 8 cm or more was an independent risk factor in women aged 45 or older (OR 7.19) (He 2017)
- A solid component or papillary projection with blood flow on Doppler ultrasound — more important than size alone
- A cyst that grows after menopause without hormone therapy, or changes shape
- Coexisting endometrial disorders (OR 4.11 in the same study) and disease lasting for decades
There is no “4–5 cm = cancer risk” rule
No study has proven a 4–5 cm cut-off for cancer — a 4 cm cyst is neither proof of safety nor a sign of cancer.
What doctors look at is whether it has grown compared with two years ago and whether its inside has changed.
Cancer types linked to endometriosis
A pooled analysis of 13 studies (Pearce 2012) linked endometriosis to
clear cell (OR 3.05), low-grade serous (OR 2.11) and endometrioid (OR 2.04) ovarian cancers,
but not to high-grade serous or mucinous types — and endometriosis-associated cancers are more often found at stage I–II
(Kim 2014).
What “mutating” really means — cell changes that build up over time
A cyst does not “mutate” overnight. Some cells may slowly accumulate genetic changes over many years, such as in the ARID1A or PIK3CA genes
(Wiegand 2010) —
and finding some of these changes in endometriosis tissue does not mean cancer
(Anglesio 2017).
3. Reading the ultrasound: reassuring versus concerning features
Direct answer: imaging features matter most — a typical endometrioma is a single-chamber cyst with a smooth wall and uniform “ground-glass” contents,
while concerning signs are a solid part, papillary projections or blood flow inside the cyst, which standard systems such as
O-RADS US
and IOTA Simple Rules / ADNEX use to grade risk.
Risk bar by O-RADS US category (approximate cancer risk)
O-RADS 0 = incomplete scan, repeat needed; O-RADS 1 = normal ovary — the category for any individual cyst must be assigned by the examining doctor (Andreotti 2020)
Table: reassuring vs concerning features — ultrasound, blood tests, symptoms and next step
Use this to talk with your doctor — not as a self-diagnosis tool
| Domain | Reassuring | Concerning | Next step |
|---|---|---|---|
| Cyst contents (ultrasound) | Single chamber, smooth wall, uniform ground-glass contents, no solid part | Solid part, papillary projections, thick irregular wall, complex multiple chambers | Concerning → MRI (O-RADS MRI) or gynecologic oncology referral |
| Size and change | Smaller or unchanged compared with the old scan | Growing after menopause, or 8 cm or more | Growing → discuss surgery without long delay |
| Blood flow (Doppler) | No blood flow inside the cyst | Blood flow within a solid part or projection | Blood flow → assessment by a gynecologic oncologist |
| Blood markers | Normal CA-125 and HE4, low ROMA, RMI under 200 | Raised CA-125 after menopause, raised HE4, high ROMA, RMI of 200–250 or more | Normal markers do not cancel out a concerning scan |
| Symptoms | No symptoms, or long-stable symptoms | Bloating, early fullness, pelvic pressure, urinary frequency more than 12 times a month, postmenopausal bleeding | Symptoms → see a doctor within a few days to 2 weeks |
Triage your pelvic symptoms before your check-up
Bloating, pelvic pressure, urinary frequency or bleeding after menopause — how urgent is it?
Analyze your severity level and receive personalized guidance from our Advisory team.
This score grades pelvic symptoms; it does not diagnose disease or tell you whether a cyst is cancer — for emergencies, use the red-flag section above.
4. How to get checked in one day — ultrasound plus blood tests in a single morning
Direct answer: many hospitals can do a transvaginal ultrasound and a CA-125 (± HE4) blood draw on the same day if you book a morning gynecology clinic.
If results are reassuring you can plan follow-up straight away; MRI or surgery usually needs another appointment only if results are borderline or concerning.
Flowchart: follow-up of an endometrioma after menopause
- Discuss options: scheduled follow-up or planned surgery
- Book the next ultrasound as your doctor advises
- Return earlier if any red flag appears
- Pelvic MRI (O-RADS MRI)
- Gynecologic oncology consult if O-RADS 4–5 or high RMI
- Plan surgery without long delay
Transvaginal ultrasound — the key test
- A transvaginal ultrasound takes about 15–30 minutes, uses no radiation, and is usually not painful
- Ask the examiner to report size, internal appearance, any solid part, blood flow, and the O-RADS category or IOTA result if possible
- Bring the scan from two years ago so the cyst can be compared for growth, shrinkage or change
Blood tests: what CA-125, HE4, ROMA and RMI can and cannot tell you
- CA-125 — not specific; before menopause endometriosis itself can raise it (at 30 U/mL, sensitivity 52% and specificity 93% for endometriosis), so it is more informative after menopause. The 2026 update of NICE NG12 uses 31 IU/mL or more at age 50–59 in women with symptoms as the threshold for an urgent ultrasound
- HE4 — rarely raised by endometriomas (mean 46.0 pM, close to 40.5 pM in healthy controls) but very high in ovarian cancer, so it separates the two better than CA-125 alone
- ROMA — combines CA-125 + HE4 + menopausal status; in postmenopausal women, sensitivity 92.3% and specificity 75.0% (Moore 2009)
- RMI = ultrasound score (0, 1 or 3) × menopausal status (1 before / 3 after menopause) × CA-125 — at a cut-off of 200, sensitivity 85% and specificity 97% (Jacobs 1990); NICE recommends referral to gynecologic cancer services at RMI I of 250 or more
- Limits: tumor markers cannot guarantee that a cyst is benign — normal results with a reassuring ultrasound lower the risk, but imaging features matter most
When MRI is needed
If the ultrasound is borderline, a contrast pelvic MRI scored with
O-RADS MRI helps separate benign from malignant — it usually needs another day, so you do not need to book several days off in advance.
Practical steps in Thai hospitals when time off is hard
- Call ahead to ask whether the gynecology clinic can do a transvaginal ultrasound and blood draw on the same morning, then book an early slot
- Bring old ultrasound reports, surgery or pathology reports, and a list of hormone drugs you have used (such as GnRH agonist, dienogest)
- If you use Universal Coverage or Social Security, have the referral letter ready before the visit so you do not need repeat trips
- Ask whether blood results come back the same day, or whether you can get them by phone or the hospital’s online channel
Three key questions to ask your doctor
- What is the size now, and has it grown, shrunk or stayed the same since two years ago?
- Is there any solid part, projection or blood flow — and which O-RADS or IOTA category is it?
- Do I need MRI or surgery, and if not, when should my next scan be?
5. Management options: surveillance, surgery or medication — a shared decision
Direct answer: for an endometrioma that persists after menopause, many gynecologists recommend laparoscopic removal of that ovary and tube
(salpingo-oophorectomy),
especially if the cyst is not shrinking, is growing, is large or has any suspicious feature; a small, simple-looking, shrinking cyst with normal blood tests may be watched instead —
it is a shared decision, and surgery advice from two years ago should be revisited with a fresh ultrasound.
Table: management options for an endometrioma after menopause
For education — generic drug names/classes only; real choices are made with your own gynecologist
| Option | Who it fits | Pros | Cons / cautions |
|---|---|---|---|
| Ultrasound + blood-marker surveillance | Small, simple-looking cyst (O-RADS 2), shrinking or stable, normal markers, no symptoms, or high surgical risk | No surgery; each check takes about one day | Needs regular attendance; no tissue confirmation; long gaps defeat the purpose of surveillance |
| Laparoscopic removal of that ovary and tube (salpingo-oophorectomy) | A cyst persisting after menopause that is not shrinking, is growing, is large or has suspicious features | Removes all at-risk tissue and gives a tissue diagnosis; usually a short hospital stay when done by laparoscopy | Surgical and anesthesia risks; adhesions from past surgery can make it harder; if cancer is suspected it should be done by a gynecologic oncologist |
| Cyst-only removal (cystectomy) | Mainly used in the reproductive years to preserve ovarian tissue — less often after menopause | Keeps the remaining ovarian tissue | Endometriosis tissue may remain and recur; less benefit from keeping the ovary after menopause |
| Hormone drug considerations (progestins such as dienogest, aromatase inhibitors such as letrozole or anastrozole, combined menopausal hormone therapy) | Postmenopausal endometriosis pain when surgery is not feasible, or menopause symptoms that need hormones | Aromatase inhibitors cut estrogen made outside the ovary; ESHRE says they may be considered if surgery is not feasible | Drugs do not tell you whether the cyst is benign; aromatase inhibitors thin bones; avoid estrogen alone |
| Weight and lifestyle | Everyone, alongside other options | Less estrogen from fat tissue; good for heart and bones after menopause | Does not reliably shrink the cyst; no supplement is proven to dissolve an endometrioma |
Why earlier surgery advice should be revisited
- Two years ago you had not reached menopause — your hormone status has changed; the cyst may have shrunk, or you may now be in a higher-risk age band
- ESHRE 2022 asks doctors to acknowledge uncertainty about cancer risk in postmenopausal women, work up any pelvic mass according to oncology guidelines, and consider surgery to obtain a tissue diagnosis
6. Reproductive-age vs postmenopausal endometrioma — how they differ
Direct answer: in the reproductive years the goals are pain control and fertility, whereas after menopause the main goal is to confirm that the cyst is benign,
because pain usually settles on its own while cancer risk tracks age and menopausal status.
Table: reproductive-age versus postmenopausal endometrioma
General trends — individuals vary
| Topic | Reproductive age | After menopause |
|---|---|---|
| Hormone driver | Cyclic ovarian estrogen every month | Low estrogen, but still some from fat tissue and aromatase within lesions |
| Pain | Period pain, pelvic pain and painful sex are common | Usually lessens or disappears — returning pain should be checked |
| Size change | Can grow or recur, even after surgery | Most stop growing or shrink — growth without hormone therapy is abnormal |
| Cancer risk and CA-125 reading | Low risk; CA-125 often raised by endometriosis, so harder to interpret | Risk rises with age; CA-125 and RMI (M = 3) become more useful |
| Usual management | Hormone drugs for symptoms; cystectomy to preserve the ovary | Ultrasound + blood tests, then surveillance or removal of that ovary and tube |
7. Can I use menopausal hormone therapy after endometriosis?
Direct answer: yes, if you need it for menopause symptoms — the ESHRE 2022 guideline says doctors may consider combined estrogen plus progestogen therapy
and should avoid estrogen-only regimens in women with a history of endometriosis, because estrogen alone may carry a higher risk of malignant transformation
(ESHRE 2022).
- Combined estrogen + progestogen is the preferred option even after hysterectomy, because the progestogen helps suppress any remaining endometriosis
- For women whose ovaries were both removed before natural menopause, ESHRE recommends continuing combined therapy at least up to the age of natural menopause
- Evidence is limited — a systematic review concluded that the absolute risk of recurrence or malignant transformation on hormone therapy cannot yet be quantified (Gemmell 2017)
- If an endometrioma is still present, have an ultrasound before starting hormones and tell your doctor promptly if pain or bleeding returns
- Overview: MedlinePlus — Hormone therapy for menopause
Frequently asked questions (FAQ)
Will a chocolate cyst shrink or disappear on its own after menopause?
Most become quiet, stop growing or get smaller because ovarian estrogen falls sharply after menopause, but not every cyst disappears. Fat tissue still makes estrogen, and endometriosis tissue can make its own local estrogen. Among 42,079 women operated on for endometriosis in Germany, about 2.55% were postmenopausal. Only an ultrasound compared with the old result can show whether a cyst has really shrunk.
I have no pain anymore. Does that mean the cyst is gone or harmless?
No pain is a real improvement in symptoms, but it is not proof that the cyst is gone or benign. Early ovarian cancer often causes no symptoms or only vague ones such as bloating, early fullness, pelvic pressure or urinary frequency. A transvaginal ultrasound with blood tests is what answers the question, especially if your last scan was more than a year ago.
How likely is a chocolate cyst to turn into cancer?
It is uncommon, but the risk is genuinely higher. Pooled studies show endometriosis raises ovarian cancer risk about 1.3 to 1.9 times. Against a general lifetime risk of about 1.1%, that is roughly 1.5 to 2%. In a Japanese cohort of 6,398 women with endometriomas, 46 developed ovarian cancer, about 0.7%, over up to 17 years, and the risk rose clearly when the cyst was diagnosed after age 50.
Is a 4 cm cyst big or a cancer risk?
No proven 4 to 5 cm size cut-off separates cancer from benign cysts, so 4 cm is neither proof of safety nor a sign of cancer. A study of women aged 45 and older having surgery for endometriomas found that a size of 8 cm or more and being postmenopausal were independent risk factors. What matters more than size is whether the cyst is growing, has a solid part or papillary projection, and has blood flow inside that part.
My CA-125 is normal. Does that rule out cancer?
No, it is not a guarantee. CA-125 is more useful after menopause, but some early cancers still give normal values, and before menopause endometriosis itself can raise CA-125. HE4 is rarely raised by endometriomas, so it helps separate the two, and ROMA combines CA-125, HE4 and menopausal status. Normal blood tests with a reassuring ultrasound lower the risk, but imaging features matter most.
Do I need several days off work, or can it be done in one day?
Many hospitals can do it in one day. Book a morning gynecology clinic slot, ask for a transvaginal ultrasound and a CA-125 blood draw on the same day, bring your old ultrasound and surgery reports, and ask three questions: how the size compares with two years ago, whether there is any solid part or blood flow and which O-RADS or IOTA category it is, and whether you need MRI or surgery. MRI or surgery may need another appointment.
My doctor recommended surgery two years ago. Do I still need it?
Revisit the decision with a fresh ultrasound rather than deciding on the absence of pain. For an endometrioma that persists after menopause, many gynecologists recommend laparoscopic removal of that ovary and tube, especially if the cyst is not shrinking, is growing, is large or has any suspicious feature. A small, simple-looking, shrinking cyst with normal blood tests may be watched instead. It is a shared decision with your doctor.
Can I use menopausal hormone therapy if I have had endometriosis?
Yes, if you need it for menopause symptoms. The ESHRE 2022 guideline says doctors may consider combined estrogen plus progestogen therapy and should avoid estrogen-only regimens in women with a history of endometriosis, even after hysterectomy, because estrogen alone may be linked to reactivation and malignant transformation. Have an ultrasound before starting and tell your doctor if pain returns.
Scientific mechanism
Estrogen withdrawal: endometriosis tissue carries estrogen receptors and grows with estrogen levels. When the ovaries stop cycling after menopause,
monthly stimulation and bleeding into the cyst stop, so inflammation and pain settle and most cysts stop growing or shrink.
Local estrogen: unlike normal endometrium, endometriosis tissue expresses the enzyme aromatase, converting androgens to estrogen itself,
and it is relatively progesterone-resistant. Together with estrogen from fat tissue, this lets lesions survive even when blood estrogen is low
(Bulun 2009).
Iron and oxidative stress: the “chocolate” in the cyst is old blood accumulated over years. Endometrioma fluid contains very high free iron
(mean 100.9 mmol/L versus 0.075 mmol/L in other cysts), which generates free radicals and ongoing DNA damage
(Yamaguchi 2008) —
one reason long-standing disease and older age are linked to risk.
Pathway to clear cell and endometrioid cancer: genetic changes build up step by step, such as loss of ARID1A
(found in 46% of clear cell and 30% of endometrioid carcinomas, and in endometriosis adjacent to the tumor) alongside activation of the PIK3CA pathway
(Wiegand 2010).
However, some of these changes occur in endometriosis with no cancer at all, so they are not an individual predictor
(Anglesio 2017).
Summarized and reviewed by Asst. Prof. Dr. Norawit Raatpiboon
Academic citations (E-E-A-T)
- Kvaskoff M et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update 2021 (PMID 33202017)
- Kim HS et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 2014 (PMID 24518590)
- Pearce CL et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012 (PMID 22361336)
- Kobayashi H et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007 (PMID 17291229)
- He ZX et al. Predictive factors of ovarian carcinoma for women with ovarian endometrioma aged 45 years and older in China. J Ovarian Res 2017 (PMID 28716151)
- Haas D et al. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012 (PMID 22562384)
- Secosan C et al. Endometriosis in Menopause: Renewed Attention on a Controversial Disease. Diagnostics 2020 (PMID 32121424)
- Gemmell LC et al. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update 2017 (PMID 28498913)
- Becker CM et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022 (PMID 35350465)
- Andreotti RF et al. O-RADS US Risk Stratification and Management System: ACR consensus guideline. Radiology 2020 (PMID 31687921)
- Thomassin-Naggara I et al. O-RADS MRI score for risk stratification of sonographically indeterminate adnexal masses. JAMA Netw Open 2020 (PMID 31977064)
- Timmerman D et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the IOTA group. Am J Obstet Gynecol 2016 (PMID 26800772)
- Van Calster B et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model. BMJ 2014 (PMID 25320247)
- Jacobs I et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status. Br J Obstet Gynaecol 1990 (PMID 2223684)
- Moore RG et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009 (PMID 18851871)
- Huhtinen K et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009 (PMID 19337252)
- Hirsch M et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG 2016 (PMID 27173590)
- Wiegand KC et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010 (PMID 20942669)
- Anglesio MS et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017 (PMID 28489996)
- Yamaguchi K et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts. Clin Cancer Res 2008 (PMID 18172249)
- Bulun SE. Endometriosis. N Engl J Med 2009 (PMID 19144942)
- NICE NG12 — Suspected cancer: recognition and referral (ovarian cancer, updated 2026) · NCI SEER — Ovarian cancer stat facts
- MedlinePlus (NIH) — Endometriosis · Ovarian cysts · Ovarian cancer · Transvaginal ultrasound
Medical disclaimer
This article provides general education about endometriomas after menopause, ovarian cancer risk and follow-up testing.
It is not a diagnosis, a personal risk assessment, or advice to have or avoid surgery — risk figures come from population studies,
and decisions must be made with a gynecologist who examines you. In an emergency, call 1669 in Thailand or your local emergency number, or go to the emergency room now.